Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir

Antiviral Research

Volumn 132, Issue , 2016, Pages 170-177

  Takashita, Emi ^a   Ejima, Miho ^a   Ogawa, Rie ^a   Fujisaki, Seiichiro ^a   Neumann, Gabriele ^b   Furuta, Yousuke ^c   Kawaoka, Yoshihiro ^b,d   Tashiro, Masato ^a   Odagiri, Takato ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c TOYAMA CHEMICAL CO LTD   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Antiviral resistance; Favipiravir; Influenza; Polymerase inhibitor; T 705

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ADAMANTANE; FAVIPIRAVIR; LANINAMIVIR; PERAMIVIR; RNA POLYMERASE; ZANAMIVIR; AMIDE; ANTIVIRUS AGENT; NA PROTEIN, INFLUENZA A VIRUS; PYRAZINE DERIVATIVE; SIALIDASE; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL THERAPY; DRUG DETERMINATION; DRUG SCREENING; HUMAN; IC50; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A VIRUS (H7N9); INFLUENZA VIRUS; NONHUMAN; ORTHOMYXOVIRIDAE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; VIRUS ISOLATION; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; CELL CULTURE; CELL LINE; CYTOPATHOGENIC EFFECT; DOSE RESPONSE; DRUG EFFECTS; INFLUENZA A VIRUS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; VIROLOGY;

AMIDES; ANTIVIRAL AGENTS; CELL LINE; CELLS, CULTURED; CYTOPATHOGENIC EFFECT, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MICROBIAL SENSITIVITY TESTS; NEURAMINIDASE; ORTHOMYXOVIRIDAE; PYRAZINES; VIRAL PROTEINS;

EID: 84975886177     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.06.007     Document Type: Article

References (36)

1. Baranovich, T., Wong, S.S., Armstrong, J., Marjuki, H., Webby, R.J., Webster, R.G., Govorkova, E.A., T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J. Virol. 87:7 (2013), 3741–3751, 10.1128/JVI.02346-12.
2. Cory, A.H., Owen, T.C., Barltrop, J.A., Cory, J.G., Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 3:7 (1991), 207–212.
3. Daikoku, T., Yoshida, Y., Okuda, T., Shiraki, K., Characterization of susceptibility variants of influenza virus grown in the presence of T-705. J. Pharmacol. Sci. 126:3 (2014), 281–284.
4. Delang, L., Segura Guerrero, N., Tas, A., Quérat, G., Pastorino, B., Froeyen, M., Dallmeier, K., Jochmans, D., Herdewijn, P., Bello, F., Snijder, E.J., de Lamballerie, X., Martina, B., Neyts, J., van Hemert, M.J., Leyssen, P., Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J. Antimicrob. Chemother. 69:10 (2014), 2770–2784, 10.1093/jac/dku209.
5. de Wit, E., Munster, V.J., van Riel, D., Beyer, W.E., Rimmelzwaan, G.F., Kuiken, T., Osterhaus, A.D., Fouchier, R.A., Molecular determinants of adaptation of highly pathogenic avian influenza H7N7 viruses to efficient replication in the human host. J. Virol. 84 (2010), 1597–1606, 10.1128/JVI.01783-09.
6. Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., Narita, H., Shiraki, K., In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46:4 (2002), 977–981, 10.1128/AAC.46.4.977-981.2002.
7. Furuta, Y., Takahashi, K., Kuno-Maekawa, M., Sangawa, H., Uehara, S., Kozaki, K., Nomura, N., Egawa, H., Shiraki, K., Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49:3 (2005), 981–986, 10.1128/AAC.49.3.981-986.2005.
8. Furuta, Y., Takahashi, K., Shiraki, K., Sakamoto, K., Smee, D.F., Barnard, D.L., Gowen, B.B., Julander, J.G., Morrey, J.D., T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antivir. Res. 82:3 (2009), 95–102, 10.1016/j.antiviral.2009.02.198.
9. Furuta, Y., Gowen, B.B., Takahashi, K., Shiraki, K., Smee, D.F., Barnard, D.L., Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir. Res. 100:2 (2013), 446–454, 10.1016/j.antiviral.2013.09.015.
10. He, X., Zhou, J., Bartlam, M., Zhang, R., Ma, J., Lou, Z., Li, X., Li, J., Joachimiak, A., Zeng, Z., Ge, R., Rao, Z., Liu, Y., Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian influenza H5N1 virus. Nature 454:7208 (2008), 1123–1126, 10.1038/nature07120.
11. Huang, W., Li, X., Cheng, Y., Tan, M., Guo, J., Wei, H., Zhao, X., Lan, Y., Xiao, N., Wang, Z., Wang, D., Shu, Y., Characteristics of oseltamivir-resistant influenza A (H1N1) pdm09 virus during the 2013-2014 influenza season in Mainland China. Virol. J., 12(96), 2015, 10.1186/s12985-015-0317-1.
12. Jin, Z., Smith, L.K., Rajwanshi, V.K., Kim, B., Deval, J., The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5’-triphosphate towards influenza A virus polymerase. PLoS One, 8(7), 2013, e68347, 10.1371/journal.pone.0068347.
13. Kiso, M., Takahashi, K., Sakai-Tagawa, Y., Shinya, K., Sakabe, S., Le, Q.M., Ozawa, M., Furuta, Y., Kawaoka, Y., T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc. Natl. Acad. Sci. U. S. A. 107:2 (2010), 882–887, 10.1073/pnas.0909603107.
14. Kupferschmidt, K., Cohen, J., Infectious diseases. Ebola drug trials lurch ahead. Science 347:6223 (2015), 701–702, 10.1126/science.347.6223.701.
15. Monto, A.S., McKimm-Breschkin, J.L., Macken, C., Hampson, A.W., Hay, A., Klimov, A., Tashiro, M., Webster, R.G., Aymard, M., Hayden, F.G., Zambon, M., Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50:7 (2006), 2395–2402, 10.1128/AAC.01339-05.
16. Obayashi, E., Yoshida, H., Kawai, F., Shibayama, N., Kawaguchi, A., Nagata, K., Tame, J.R., Park, S.Y., The structural basis for an essential subunit interaction in influenza virus RNA polymerase. Nature 454:7208 (2008), 1127–1131, 10.1038/nature07225.
17. Octaviani, C.P., Ozawa, M., Yamada, S., Goto, H., Kawaoka, Y., High level of genetic compatibility between swine-origin H1N1 and highly pathogenic avian H5N1 influenza viruses. J. Virol. 84:20 (2010), 10918–10922, 10.1128/JVI.01140-10.
18. Oestereich, L., Lüdtke, A., Wurr, S., Rieger, T., Muñoz-Fontela, C., Günther, S., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antivir. Res. 105 (2014), 17–21, 10.1016/j.antiviral.2014.02.014.
19. Okomo-Adhiambo, M., Fry, A.M., Su, S., Nguyen, H.T., Elal, A.A., Negron, E., Hand, J., Garten, R.J., Barnes, J., Xiyan, X., Villanueva, J.M., Gubareva, L.V., 2013–14 US Influenza Antiviral Working Group. Oseltamivir-resistant influenza A(H1N1)pdm09 viruses, United States, 2013–14. Emerg. Infect. Dis. 21:1 (2015), 136–141, 10.3201/eid2101.141006.
20. Rocha-Pereira, J., Nascimento, M.S., Ma, Q., Hilgenfeld, R., Neyts, J., Jochmans, D., The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon. Antimicrob. Agents Chemother. 58:8 (2014), 4675–4681, 10.1128/AAC.02546-13.
21. Sangawa, H., Komeno, T., Nishikawa, H., Yoshida, A., Takahashi, K., Nomura, N., Furuta, Y., Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob. Agents Chemother. 57:11 (2013), 5202–5208, 10.1128/AAC.00649-13.
22. Sidwell, R.W., Barnard, D.L., Day, C.W., Smee, D.F., Bailey, K.W., Wong, M.H., Morrey, J.D., Furuta, Y., Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob. Agents Chemother. 51:3 (2007), 845–851, 10.1128/AAC.01051-06.
23. Sleeman, K., Mishin, V.P., Deyde, V.M., Furuta, Y., Klimov, A.I., Gubareva, L.V., In vitro antiviral activity of favipiravir (t-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob. Agents Chemother. 54:6 (2010), 2517–2524, 10.1128/AAC.01739-09.
24. Smee, D.F., Huffman, J.H., Morrison, A.C., Barnard, D.L., Sidwell, R.W., Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob. Agents Chemother. 45:3 (2001), 743–748, 10.1128/AAC.45.3.743-748.2001.
25. Smither, S.J., Eastaugh, L.S., Steward, J.A., Nelson, M., Lenk, R.P., Lever, M.S., Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antivir. Res. 104 (2014), 153–155, 10.1016/j.antiviral.2014.01.012.
26. Squires, R.B., Noronha, J., Hunt, V., García-Sastre, A., Macken, C., Baumgarth, N., Suarez, D., Pickett, B.E., Zhang, Y., Larsen, C.N., Ramsey, A., Zhou, L., Zaremba, S., Kumar, S., Deitrich, J., Klem, E., Scheuermann, R.H., Influenza research database: an integrated bioinformatics resource for influenza research and surveillance. Influ. Other Respir. Viruses 6:6 (2012), 404–416, 10.1111/j.1750-2659.2011.00331.x.
27. Takashita, E., Fujisaki, S., Kishida, N., Xu, H., Imai, M., Tashiro, M., Odagiri, T., Influenza Virus Surveillance Group of Japan. Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan. Influ. Other Respir. Viruses 7:6 (2013), 1390–1399, 10.1111/irv.12132.
28. Takashita, E., Ejima, M., Itoh, R., Miura, M., Ohnishi, A., Nishimura, H., Odagiri, T., Tashiro, M., A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Euro Surveill., 19(1), 2014 pii=20666 http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20666.
29. Takashita, E., Kiso, M., Fujisaki, S., Yokoyama, M., Nakamura, K., Shirakura, M., Sato, H., Odagiri, T., Kawaoka, Y., Tashiro, M., The Influenza Virus Surveillance Group of Japan. Characterization of a large cluster of influenza A(H1N1)pdm09 virus cross-resistant to oseltamivir and peramivir during the 2013/2014 influenza season in Japan. Antimicrob. Agents Chemother. 59:5 (2015), 2607–2617, 10.1128/AAC.04836-14.
30. Takashita, E., Meijer, A., Lackenby, A., Gubareva, L., Rebelo-de-Andrade, H., Besselaar, T., Fry, A., Gregory, V., Leang, S.K., Huang, W., Lo, J., Pereyaslov, D., Siqueira, M.M., Wang, D., Mak, G.C., Zhang, W., Daniels, R.S., Hurt, A.C., Tashiro, M., Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014. Antivir. Res. 117 (2015), 27–38, 10.1016/j.antiviral.2015.02.003.
31. Tashiro, M., McKimm-Breschkin, J.L., Saito, T., Klimov, A., Macken, C., Zambon, M., Hayden, F.G., Neuraminidase Inhibitor Susceptibility Network. Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996–2007. Antivir. Ther. 14:6 (2009), 751–761, 10.3851/IMP1194.
32. Ujike, M., Shimabukuro, K., Mochizuki, K., Obuchi, M., Kageyama, T., Shirakura, M., Kishida, N., Yamashita, K., Horikawa, H., Kato, Y., Fujita, N., Tashiro, M., Odagiri, T., Working Group for Influenza Virus Surveillance in Japan. Oseltamivir-resistant influenza viruses A(H1N1) during 2007-2009 influenza seasons. Jpn. Emerg. Infect. Dis. 16:6 (2010), 926–935, 10.3201/eid1606.091623.
33. Ujike, M., Ejima, M., Anraku, A., Shimabukuro, K., Obuchi, M., Kishida, N., Hong, X., Takashita, E., Fujisaki, S., Yamashita, K., Horikawa, H., Kato, Y., Oguchi, A., Fujita, N., Tashiro, M., Odagiri, T., Influenza Virus Surveillance Group of Japan. Monitoring and characterization of oseltamivir resistant pandemic (H1N1) 2009 virus, Japan, 2009–2010. Emerg. Infect. Dis. 17:3 (2011), 470–479, 10.3201/eid1703.101188.
34. Watanabe, T., Kiso, M., Fukuyama, S., Nakajima, N., Imai, M., Yamada, S., Murakami, S., Yamayoshi, S., Iwatsuki-Horimoto, K., Sakoda, Y., Takashita, E., McBride, R., Noda, T., Hatta, M., Imai, H., Zhao, D., Kishida, N., Shirakura, M., de Vries, R.P., Shichinohe, S., Okamatsu, M., Tamura, T., Tomita, Y., Fujimoto, N., Goto, K., Katsura, H., Kawakami, E., Ishikawa, I., Watanabe, S., Ito, M., Sakai-Tagawa, Y., Sugita, Y., Uraki, R., Yamaji, R., Eisfeld, A.J., Zhong, G., Fan, S., Ping, J., Maher, E.A., Hanson, A., Uchida, Y., Saito, T., Ozawa, M., Neumann, G., Kida, H., Odagiri, T., Paulson, J.C., Hasegawa, H., Tashiro, M., Kawaoka, Y., Characterization of H7N9 influenza A viruses isolated from humans. Nature 501:7468 (2013), 551–555, 10.1038/nature12392.
35. World Health Organization, Laboratory Methodologies for Testing the Antiviral Susceptibility of Influenza Viruses: Reference Viruses for Validation and Controls. 2012 (accessed 28.07.15.) http://www.who.int/influenza/gisrs_laboratory/antiviral_susceptibility/referenceviruses/en/index.html.
36. World Health Organization, Meetings of the WHO working group on surveillance of influenza antiviral susceptibility-Geneva, November 2011 and June 2012. Wkly. Epidemiol. Rec. 87:39 (2012), 369–374.